Calmark's Neo product for bilirubin is registered in Turkey
Calmark Sweden AB (publ) announced today that the company’s point-of-care test for bilirubin has been registered in Turkey. The registration covers both the test cassette Neo-Bilirubin and the instrument, POC-Analyzer Neo. Today's announcement means sales of Calmark Neo-Bilirubin can start in Turkey.
Calmark cooperates with the company Savas Medikal regarding launch, registration and sales on the Turkish market. The company has now listed Calmark's product in the country's "Product Tracking System", which means that sales can start. Savas Medikal and Calmark have a detailed plan in place for the launch of near-patient bilirubin analysis on newborns.
Turkey has 85 million inhabitants and approximately 1.3 million children are born per year in the country.
"We are very happy that the registration is in place in Turkey, so we can now start the launch," comments CEO Anna Söderlund.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-09-2023 17:31 CET.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.